MEASURING DISEASE AND TREATMENT-RELATED SYMPTOMS AND HRQOL IMPACTS IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) USING THE EORTC QLQ-C30 AND NMIBC-24: QUALITATIVE LITERATURE REVIEW AND GAP ANALYSIS

被引：0
|
作者：
Mason, B. [1 ]
Eccleston, A. [2 ]
Ayala, Nunes L. [1 ]
Chandrasekar, S. [3 ]
Leventi, A. [1 ]
Gater, A. [1 ]
Chang, J. [3 ]
机构：
[1] Adelphi Values Ltd, Bollington, England
[2] Pfizer Inc, Edinburgh EDH, Midlothian, Scotland
[3] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCR171
引用
收藏
页码：S327 / S328
页数：2
相关论文
共 13 条
  • [1] Combination therapy in high-risk non-muscle invasive bladder cancer (HR-NMIBC) with and without BCG prior treatment
    Rexer, H.
    Ohlmann, C. -H.
    Grimm, M. -O.
    UROLOGIE, 2023, 62 (03): : 338 - 339
  • [2] DRIVERS OF TREATMENT PREFERENCES IN HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) PATIENTS: QUALITATIVE INTERVIEWS TO INFORM A PATIENT-PREFERENCE STUDY
    Mason, B.
    Eccleston, A.
    Gater, A.
    Hauber, B.
    Thompson, A.
    Coulter, J.
    Guy, M.
    Nunes, Ayala L.
    Brinkmann, J.
    Hallworth, P.
    Cappelleri, J.
    Bell, B.
    Chang, J.
    Satkunasivam, R.
    VALUE IN HEALTH, 2023, 26 (12) : S494 - S495
  • [3] Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
    Musat, Mihaela Georgiana
    Kwon, Christina Soeun
    Masters, Elizabeth
    Sikirica, Slaven
    Pijush, Debduth B.
    Forsythe, Anna
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 35 - 48
  • [4] [18F]-FDG PET/CT FOR BLADDER CANCER STAGING AND DECISION-MAKING IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC)
    Hurle, Rodolfo
    Casale, Paolo
    Saita, Alberto
    Buffi, NicoloMaria
    Lughezzani, Giovanni
    Contieri, Roberto
    Fasulo, Vittorio
    Frego, Nicola
    Benetti, Alessio
    Chiti, Arturo
    Rodari, Marcello
    Sollini, Martini
    Pini, Cristiano
    Gelardi, Fabrizia
    Guazzoni, Giorgio
    Lazzeri, Massimo
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1010 - E1010
  • [5] [18F]-FDG PET/CT for bladder cancer staging and decision-making in patients with High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)
    Hurle, R.
    Gobbo, A.
    Casale, P.
    Saita, A.
    Buffi, N.
    Lughezzani, G.
    Sollini, M.
    Rodari, M.
    Pini, C.
    Gelardi, F.
    Contieri, R.
    Guazzoni, G.
    Chiti, A.
    Lazzeri, M.
    EUROPEAN UROLOGY, 2022, 81 : S358 - S359
  • [6] Secondary Prevention of non-muscle invasive Bladder Cancer (NMIBC): Randomized Phase 2 Trial of Erdafitinib versus intravesical Chemotherapy of investigator's Choice in Patients with High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) and Recurrence and post FGFR Mutations or Fusions Immunotherapy with Bacillus Calmette-Guerin (BCG) (THOR-2) - AB 78/21 of the AUO
    Rexer, Heidrun
    Kramer, Mario
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2022, 53 (04) : 314 - 315
  • [7] HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) TREATED WITH SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION MITOMYCIN-C (EMDA-MMC): 2% DISEASE-SPECIFIC MORTALITY AT 4 YEARS' FOLLOW-UP
    Gan, Christine
    Amery, Suzanne
    Chatterton, Kathryn
    Khan, Muhammad Shamim
    Thomas, Kay
    O' Brien, Tim
    JOURNAL OF UROLOGY, 2017, 197 (04): : E367 - E367
  • [8] Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC)
    Linscott, Joshua
    Miyagi, Hiroko
    Gould, Billie
    Murthy, Prithvi
    Rose, Kyle M.
    Camperlengo, Lucia P.
    Bonora, Giancarlo
    Zemp, Logan
    Gilbert, Scott Michael
    Spiess, Philippe E.
    Sexton, Wade J.
    Meeks, Joshua J.
    Du, Pan
    Jia, Shidong
    Li, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Bacillus Calmette-Guérin (BCG) treatment patterns and real-world outcomes in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): A systematic literature review (SLR).
    Eccleston, Anthony
    Koshy, Abin
    Musat, Mihaela Georgiana
    Tzonev, Cristiana
    Brinkmann, Julia
    Chang, Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [10] Combination Therapy for Patients with High-risk non-muscle invasive Bladder Cancer (HR-NMIBC) A randomized, open-label, multi-center, world-wide, Phase III Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as a Combination Therapy compared to BCG alone in Patients with High-risk non-muscle invasive Bladder Cancer (POTOMAC) - AB 69/18 of the AUO
    Rexer, H.
    Merseburger, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2019, 50 (04) : 345 - 346
12